The gene FGFR4 (fibroblast growth factor receptor 4) is mapped to human chromosome 5q35.2. It belongs to the fibroblast growth factor receptor (FGFR) tyrosine kinase family of proteins. The protein has three extracellular immunoglobulin-type domains (D1-D3), a single-span transmembrane domain and an intracellular split tyrosine kinase domain.
Synonyms: Anti-CD334; Anti-JTK2; Anti-fibroblast growth factor receptor 4
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: FGFRs (fibroblast growth factor receptors) control various cellular processes such as cell growth, differentiation, survival and migration. FGFR4 is an oncogene and is associated with tumor development. It is associated with colorectal cancer, ovarian cancer and hepatocellular carcinoma. It binds to FGFs (fibroblast growth factors), multifunctional proteins involved in angiogenesis, wound healing and embryonic development.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC